A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
- Vergote, Ignace
- Smith, David C
- Berger, Raanan
- Kurzrock, Razelle
- Vogelzang, Nicholas J
- Sella, Avishay
- Wheler, Jennifer
- Lee, Yihua
- Foster, Paul G
- Weitzman, Ron
- Buckanovich, Ronald J
Publication date
September 2017
DOI Publisher
Elsevier BV Journal
European Journal of CancerAbstract
Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor receptor 2 and MET, was assessed in a cohort of ovarian carcinoma patients as part of a phase 2 randomised discontinuation trial (RDT) with cohorts from nine different tumour types.status: publishe
Add to ORKG